Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field

Kohei Hara, Shigeru Kohno, Jun Ichi Kadota, Kazunori Tomono, Yoichi Hirakata, Shigefumi Maesaki, Masao Nakatomi, Sadahiro Asai, Kazuhiro Okuno, Naomi Itoh, Yuichi Inoue, Yuko Yamashita, Takao Koike, Katsunori Onishi, Mitsuhide Omichi, Yomei Hiraga, Akira Watanabe, Toshihiro Nukiwa, Kazuo Sato, Toshio NakamuraMasaaki Arakawa, Kouichi Wada, Kenichi Igarashi, Yoshinori Shimazu, Yukiyoshi Kon, Hiroyuki Sega, Osamu Sekine, Yasutoshi Suzuki, Nobuki Aoki, Takao Takizawa, Toshinori Kanemura, Hisashi Takemura, Kohshu Nagao, Yoshio Hamashima, Yoshio Sakamoto, Kenji Sakata, Takeo Toyoda, Mitsuhiko Ohsumi, Yukio Noguchi, Hiroyuki Kobayashi, Shin Kawai, Hiroshi Sugiura, Susumu Sakayori, Hiroshi Oshitani, Takashi Inamatsu, Yoshishige Masuda, Yasuyuki Sano, Yasuo Arai, Chuhei Ogawa, Hirokazu Yamada, Kohya Shiba, Masaki Yoshida, Kazuhisa Okada, Tetsuo Sato, Futoshi Kotajima, Izumi Hayashi, Harumi Shishido, Atsuyuki Kurashima, Fumio Matsumoto, Iwao Sakurai, Jingoro Shimada, Shigeki Odagiri, Kaneo Suzuki, Yuji Watanuki, Kenichi Takahashi, Toshiyuki Yamamoto, Kaoru Shimokata, Hidehiko Saito, Shuzo Sakai, Keisuke Nishiwaki, Masashi Yamamoto, Masamitsu Iwata, Hiroshi Saito, Fumio Miki, Nobuhiro Narita, Keiichi Mikasa, Yoshihito Niki, Toshiharu Matsushima, Rinzo Soejima, Yoshiro Sawae, Koji Takaki, Kotaro Oizumi, Shouji Kinoshita, Yoshiyuki Mitsutake, Fumio Tanaka, Masashi Kawahara, Tsuyoshi Nagatake, Yoshiaki Utsunomiya, Moritoshi Akiyama, Masaru Nasu, Atsuro Hashimoto, Shigeru Matsukura, Hideo Mashimoto, Kazuhito Hiratani, Atsushi Saito, Masao Tateyama, Takashi Shinzato, Hiroyuki Uechi, Futoshi Higa

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)

    Abstract

    The efficacy, safety and usefulness of injectable ciprofloxacin (CPFX) were investigated in a clinical study involving treatment of patients with severe and/or refractory infections in the internal medicine field. The test drug was administered by intravenous drip infusion at a dose of 300 mg (as CPFX), twice daily for 3 to 14 days. A total of 66 cases were enrolled in this study: 16 cases with chronic bronchitis, 23 with infectious bronchiectasis, 20 with secondary infection with chronic respiratory disease and 2 with empyema, but 5 cases had ineligible diseases. The clinical efficacy rate was 69.1% (38/55 cases), being 92.3% (12/13) for chronic bronchitis, 59.1% (13/22) for infectious bronchiectasis, 72.2% (13/18) for secondary infection with chronic respiratory disease. The subtotals were 71.7% (38/53) for the above chronic lower RTIs and 0/2 for empyema. The efficacy rate in poor responders to antibiotic pretreatment was 66.7% (8/12 cases). The elimination rate of causative organisms was 65.7% (23/35 strains), in terms of bacteriological efficacy. Side effects were noted in 11.3% (7/62) with 10 events. The major signs and symptoms were central nervous system disorders and gastro-intestinal symptoms, all of which were mild to moderate, and disappeared during treatment or after the completion of treatment or drug discontinuation. Abnormal laboratory findings were seen in 13.1% (8/61) with 19 events, mostly GOT, GPT and/or γ -GTP elevation. In the evaluation of overall safety, a safety rate of 77.4% (48/62 cases) was obtained, yielding a 62.1% (36/58 cases) usefulness rate. Therefore, the present study confirmed good effectiveness and safety for injectable CPFX in the treatment of severe and/or refractory chronic airway infections.

    Original languageEnglish
    Pages (from-to)933-935
    Number of pages3
    JournalJapanese Journal of Chemotherapy
    Volume45
    Issue number11
    Publication statusPublished - 1997

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field'. Together they form a unique fingerprint.

    Cite this